• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Immunological Approaches to the Treatment of New Coronavirus Infection (Review).免疫治疗新型冠状病毒感染的方法(综述)。
Sovrem Tekhnologii Med. 2021;13(3):81-99. doi: 10.17691/stm2021.13.3.09. Epub 2021 Jun 28.
2
Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review.新冠病毒肺炎患者细胞因子风暴及细胞因子靶向治疗的危害:综述
J Med Internet Res. 2020 Aug 13;22(8):e20193. doi: 10.2196/20193.
3
Similarities and Dissimilarities of COVID-19 and Other Coronavirus Diseases.新型冠状病毒病与其他冠状病毒病的异同。
Annu Rev Microbiol. 2021 Oct 8;75:19-47. doi: 10.1146/annurev-micro-110520-023212. Epub 2021 Jan 25.
4
Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic.深入探讨针对致命性 COVID-19 大流行的潜在治疗药物的药理学研究
Eur J Pharmacol. 2021 Jan 5;890:173643. doi: 10.1016/j.ejphar.2020.173643. Epub 2020 Oct 13.
5
Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management.新型冠状病毒病 2019(COVID-19):免疫病理学、血清学诊断和治疗概述。
Scand J Immunol. 2021 Apr;93(4):e12998. doi: 10.1111/sji.12998. Epub 2020 Dec 3.
6
Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.设计治疗策略以对抗严重急性呼吸综合征冠状病毒 2 型疾病:COVID-19。
Drug Dev Res. 2021 Feb;82(1):12-26. doi: 10.1002/ddr.21720. Epub 2020 Jul 30.
7
SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.SARS-CoV-2 与人类宿主的多方面相互作用。第一部分:迄今为止我们所了解和所做的,以及仍然未知的现实。
IUBMB Life. 2020 Nov;72(11):2313-2330. doi: 10.1002/iub.2380. Epub 2020 Sep 12.
8
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection.用于新冠治疗和新冠病毒检测的单克隆抗体。
J Biomed Sci. 2022 Jan 4;29(1):1. doi: 10.1186/s12929-021-00784-w.
9
Molecular Insights into Severe Acute Respiratory Syndrome Coronavirus 2 Pathobiology: Dissecting the Interplay between Cellular Innate Immunity and Immune Evasion.深入了解严重急性呼吸综合征冠状病毒 2 发病机制的分子机制:剖析细胞固有免疫与免疫逃避之间的相互作用。
Crit Rev Immunol. 2020;40(6):485-496. doi: 10.1615/CritRevImmunol.2020035855.
10
Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.环孢素 A 通过三种 SARS-CoV-2 变体抑制肺细胞中的病毒感染和释放以及细胞因子产生。
Microbiol Spectr. 2022 Feb 23;10(1):e0150421. doi: 10.1128/spectrum.01504-21. Epub 2022 Jan 5.

引用本文的文献

1
Jet Injection of Naked mRNA Encoding the RBD of the SARS-CoV-2 Spike Protein Induces a High Level of a Specific Immune Response in Mice.喷射注射编码严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白受体结合域(RBD)的裸露信使核糖核酸(mRNA)可在小鼠体内诱导高水平的特异性免疫反应。
Vaccines (Basel). 2025 Jan 13;13(1):65. doi: 10.3390/vaccines13010065.
2
A Review of the Potential Effects of Melatonin in Compromised Mitochondrial Redox Activities in Elderly Patients With COVID-19.褪黑素对老年 COVID-19 患者线粒体氧化还原活性受损的潜在影响综述
Front Nutr. 2022 Jun 20;9:865321. doi: 10.3389/fnut.2022.865321. eCollection 2022.
3
Immune-based therapeutic approaches in COVID-19.COVID-19 的免疫治疗方法。
Biomed Pharmacother. 2022 Jul;151:113107. doi: 10.1016/j.biopha.2022.113107. Epub 2022 May 16.

本文引用的文献

1
Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients.致病性T细胞和炎性单核细胞在重症COVID-19患者中引发炎症风暴。
Natl Sci Rev. 2020 Jun;7(6):998-1002. doi: 10.1093/nsr/nwaa041. Epub 2020 Mar 13.
2
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.单剂 Ad26.COV2.S 疫苗预防新冠病毒的安全性和有效性。
N Engl J Med. 2021 Jun 10;384(23):2187-2201. doi: 10.1056/NEJMoa2101544. Epub 2021 Apr 21.
3
Convalescent plasma to treat COVID-19: clinical experience and efficacy.恢复期血浆治疗 COVID-19:临床经验和疗效。
Aging (Albany NY). 2021 Mar 18;13(6):7758-7766. doi: 10.18632/aging.202795.
4
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.基于 rAd26 和 rAd5 载体的异源初免-加强型 COVID-19 疫苗的安全性和有效性:俄罗斯一项随机对照 3 期临床试验的中期分析。
Lancet. 2021 Feb 20;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8. Epub 2021 Feb 2.
5
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19.恢复期血浆抗体水平与新冠死亡风险。
N Engl J Med. 2021 Mar 18;384(11):1015-1027. doi: 10.1056/NEJMoa2031893. Epub 2021 Jan 13.
6
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
7
Trained immunity as a novel approach against COVID-19 with a focus on Bacillus Calmette-Guérin vaccine: mechanisms, challenges and perspectives.训练有素的免疫:一种对抗 COVID-19 的新方法,重点关注卡介苗:机制、挑战与前景
Clin Transl Immunology. 2020 Dec 22;9(12):e1228. doi: 10.1002/cti2.1228. eCollection 2020.
8
Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19: a retrospective study.新型冠状病毒肺炎患者疾病严重程度与炎症相关参数的相关性分析:一项回顾性研究。
BMC Infect Dis. 2020 Dec 21;20(1):963. doi: 10.1186/s12879-020-05681-5.
9
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.REGN-COV2,一种中和抗体鸡尾酒疗法,用于治疗门诊新冠患者。
N Engl J Med. 2021 Jan 21;384(3):238-251. doi: 10.1056/NEJMoa2035002. Epub 2020 Dec 17.
10
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020.免疫实践咨询委员会关于使用辉瑞-BioNTech COVID-19 疫苗的临时建议-美国,2020 年 12 月。
MMWR Morb Mortal Wkly Rep. 2020 Dec 18;69(50):1922-1924. doi: 10.15585/mmwr.mm6950e2.

免疫治疗新型冠状病毒感染的方法(综述)。

Immunological Approaches to the Treatment of New Coronavirus Infection (Review).

机构信息

Associate Professor, Department of Propedeutics of Internal Diseases; Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia.

Assistant, Department of Propedeutics of Internal Diseases; Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia.

出版信息

Sovrem Tekhnologii Med. 2021;13(3):81-99. doi: 10.17691/stm2021.13.3.09. Epub 2021 Jun 28.

DOI:10.17691/stm2021.13.3.09
PMID:34603758
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8482822/
Abstract

The pandemic of the new coronavirus infection (COVID-19) caused by the SARS-CoV-2 virus has spread all over the world. The large amount of information that appears every day requires comprehension and systematization. The immunological aspects of the virus-host interaction are the core issues in the effective treatment and prevention of COVID-19' development. The review analyzes the known pathways of the viral invasion and evasion, the mechanisms of the cytokine storm, endothelial damage, and hypercoagulability associated with SARS-CoV-2 infection. Clinical data from previous SARS and MERS epidemics is discussed here. We also address the therapeutic approaches based on the basic knowledge of immune response and the blood cells' immune functions, as well as the ways to reduce their hyperactivation. The use of interferon therapy, anti-inflammatory therapy, anti-cytokine therapy, neutralizing antibodies, convalescent plasma, and mesenchymal stem cells, as well as prophylactic vaccines, is discussed.

摘要

由 SARS-CoV-2 病毒引起的新型冠状病毒感染(COVID-19)大流行已在全球范围内蔓延。每天出现的大量信息需要理解和系统化。病毒-宿主相互作用的免疫学方面是有效治疗和预防 COVID-19 发展的核心问题。该综述分析了已知的病毒入侵和逃逸途径、细胞因子风暴、内皮损伤和与 SARS-CoV-2 感染相关的高凝机制。本文还讨论了基于免疫反应基础知识和血细胞免疫功能的治疗方法,以及降低其过度激活的方法。讨论了干扰素治疗、抗炎治疗、抗细胞因子治疗、中和抗体、恢复期血浆和间充质干细胞以及预防性疫苗的使用。